Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

Abstract excerpt

Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed. Drug resistance to NAs is produced by a combination of viral, host and antiviral drug factors....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis B Virus Studies
• Share to Hepatitis C virus research
• Share to HIV/AIDS drug development and treatment